Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors

The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and upside.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Financial Health Rating WM Technology (MAPS) $0.3711 $67.77M ★★★★★★ LexinFintech Holdings (LX) $2.29 $371.86M ★★★★★★ FinVolution Group (FINV) $4.98 $1.25B ★★★★★☆ Tuniu (TOUR) $0.73 $82.89M ★★★★★★ Information Services Group (III) $3.11 $187.84M ★★★★★★ Golden Growers Cooperative (GGRO.U) $5.00 $77.45M ★★★★★★ Niagen Bioscience (NAGE) $4.61 $361.11M ★★★★★★ LifeVantage (LFVN) $4.17 $53.14M ★★★★★★ SIGA Technologies (SIGA) $7.80 $312.37M ★★★★★★ BAB (BABB) $0.875 $6.5M ★★★★★★

Click here to see the full list of 355 stocks from our US Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Oramed Pharmaceuticals

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Oramed Pharmaceuticals Inc. focuses on the research and development of pharmaceutical solutions utilizing a technology platform for the oral delivery of therapeutic proteins, with a market cap of approximately $142.78 million.

Operations: The company's revenue is primarily derived from research and development activities related to its proprietary products and technologies, totaling $2 million.

Market Cap: $142.78M

Oramed Pharmaceuticals has transitioned to profitability, reporting a net income of US$64.05 million for 2025 compared to a loss the previous year. Despite limited revenue of US$2 million, its strong financial position is underscored by no debt and significant short-term assets exceeding liabilities. The management and board are experienced, with an average tenure of over seven years. The company completed a share buyback program, repurchasing nearly 4.77% of shares for US$4.63 million, indicating confidence in its valuation at a low price-to-earnings ratio of 2.4x compared to the broader market's 19.2x.

Get an in-depth perspective on Oramed Pharmaceuticals' performance by reading our balance sheet health report here. Understand Oramed Pharmaceuticals' track record by examining our performance history report.ORMP Financial Position Analysis as at Apr 2026

Cerus

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market cap of $363.20 million.

Story Continues

Operations: The company generates revenue primarily from its Blood Safety segment, which reported $206.13 million.

Market Cap: $363.2M

Cerus Corporation, with a market cap of US$363.20 million, is navigating its unprofitable status by focusing on revenue growth and operational stability. The company reported US$206.13 million in revenue from its Blood Safety segment and forecasts further growth to US$224-228 million for 2026. While Cerus has seen losses decrease by 25.6% annually over five years, it maintains a stable cash runway exceeding three years due to positive free cash flow growth of 33.8%. Recent leadership changes may influence strategic direction as Vivek Jayaraman steps into the CEO role in July 2026, succeeding long-serving CEO William Greenman.

Click here to discover the nuances of Cerus with our detailed analytical financial health report. Examine Cerus' earnings growth report to understand how analysts expect it to perform.CERS Financial Position Analysis as at Apr 2026

LifeMD

Simply Wall St Financial Health Rating: ★★★★★★

Overview: LifeMD, Inc. is a direct-to-patient telehealth company providing virtual medical care and pharmacy services in the United States, with a market cap of $166.47 million.

Operations: The company generates revenue from its telehealth segment, which amounts to $194.06 million.

Market Cap: $166.47M

LifeMD, Inc., with a market cap of US$166.47 million, is advancing its telehealth services despite being unprofitable. The company has shown significant revenue growth from its telehealth segment, reporting US$194.06 million in revenue and forecasting between US$220 million to US$230 million for 2026. Recent initiatives include offering the newly FDA-approved weight management drug Foundayo through an integration with LillyDirect, enhancing LifeMD's service offerings in weight management care. The company maintains a stable cash runway exceeding three years and remains debt-free, providing financial flexibility amidst ongoing strategic leadership changes within its executive team.

Click to explore a detailed breakdown of our findings in LifeMD's financial health report. Review our growth performance report to gain insights into LifeMD's future.LFMD Financial Position Analysis as at Apr 2026

Seize The Opportunity

Embark on your investment journey to our 355 US Penny Stocks selection here. Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ORMPCERS and LFMD.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments